Damian Garde

New York

Reporter at Bloomberg News

@business reporter covering pharma / [email protected] / Signal: damiangarde.67

Featured in: Favicon

statnews.com Favicon

businessinsider.com Favicon

foxnews.com Favicon

scribd.com Favicon

time.com

pbs.org

boston.com Favicon

scientificamerican.com Favicon

bostonglobe.com Favicon

theweek.com + 88 more

Articles

Cancer Treatment Studies, Walking and Early Immunotherapy, at ASCO

3 days ago | bloomberg.com | Robert Langreth |Damian Garde

Hi, it’s Bob from Chicago, where I spent my weekend talking to oncologists. And it’s Damian in New York, where I monitored the cancer conference from afar. Here’s what we learned. But first ... Every year around this time, some 40,000 oncologists and oncology drug developers from around the world descend on the massive convention center here in Chicago for the American Society of Clinical Oncology annual meeting.
Immunotherapy Drugs Show Major Progress in Early-Stage Cancer

5 days ago | news.bloomberglaw.com | Robert Langreth |Damian Garde

Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier stages, a development primed to expand their use and transform care for stubborn diseases like gastric and colon cancer. Immunotherapy treatments such as Opdivo from Bristol Myers Squibb Co., Imfinzi from AstraZeneca PLC, and Roche Holding AG’s Tecentriq have become bestsellers by increasing survival times in a number of advanced cancers.
Immunotherapy Drugs Show Major Progress in Early-Stage Cancer

5 days ago | bloomberg.com | Robert Langreth |Damian Garde

Saline Drip Hanging On Metal Hook Against Wall In Hospital rf IV hospital(Bloomberg) -- Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier stages, a development primed to expand their use and transform care for stubborn diseases like gastric and colon cancer.
RFK Jr. MAHA Report on Child Health Didn't Hammer Industries

2 weeks ago | bloomberg.com | Damian Garde

Hi, it’s Damian in New York. US manufacturers had been bracing for fallout from a MAHA report. Now it looks like they can enjoy their long weekends. But before I tell you more ... Robert F. Kennedy Jr.’s ascent to head of US health policy promised to bring about radical change by cleaning up foods, policing medicines and reining in the influence of corporate profiteers, all in the name of making America healthy again.
Pfizer Hits FDA Setback in Effort to Boost Prostate Cancer Drug

2 weeks ago | news.bloombergtax.com | Damian Garde

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
Pfizer Hits FDA Setback in Effort to Boost Prostate Cancer Drug

2 weeks ago | news.bloomberglaw.com | Damian Garde

Pfizer Inc. failed to convince advisers to the US Food and Drug Administration to support a dramatic expansion in the use of its prostate cancer drug, a setback that could scuttle the company’s blockbuster ambitions for the treatment. A group of independent experts voted unanimously that Pfizer didn’t present convincing data to broaden the approval of Talzenna, a pill currently cleared for a group of patients with prostate cancer that has specific genetic mutations.
Pfizer Hits FDA Setback in Effort to Boost Prostate Cancer Drug

2 weeks ago | bloomberg.com | Damian Garde

The Pfizer Inc. offices in Madrid, Spain, on Wednesday, April 23, 2025. Spain has risen to the top of European rankings for clinical trials, using some of the region’s most generous tax breaks and a relatively speedy regulatory process to reduce the lag from the start of a drug trial to approval. Photographer: Emilio Parra Doiztua/Bloomberg(Bloomberg) -- Pfizer Inc.
Roche Needs More US Data on Key Cancer Drug, FDA Advisers Say

2 weeks ago | news.bloombergtax.com | Damian Garde

A group of advisers to the Food and Drug Administration said Roche Holding AG needs to study its blood cancer treatment in more American patients before its use can be expanded. Independent experts voted eight-to-one that the results of a pivotal Roche trial, which enrolled just 9% of its total patients from the US, weren’t applicable to the domestic population. They asked the Swiss company to gather more data.
Roche Needs More US Data on Key Cancer Drug, FDA Advisers Say

2 weeks ago | bloomberg.com | Damian Garde

The Roche Holding AG headquarters in Basel, Switzerland. (Bloomberg) -- A group of advisers to the Food and Drug Administration said Roche Holding AG needs to study its blood cancer treatment in more American patients before its use can be expanded. Independent experts voted eight-to-one that the results of a pivotal Roche trial, which enrolled just 9% of its total patients from the US, weren’t applicable to the domestic population. They asked the Swiss company to gather more data.
Roche Needs More US Data on Key Cancer Drug, FDA Advisers Say

2 weeks ago | news.bloomberglaw.com | Damian Garde

A group of advisers to the Food and Drug Administration said Roche Holding AG needs to study its blood cancer treatment in more American patients before its use can be expanded. Independent experts voted eight-to-one that the results of a pivotal Roche trial, which enrolled just 9% of its total patients from the US, weren’t applicable to the domestic population. They asked the Swiss company to gather more data.